Hyperoside Modulates the Estrogen‐PI3K/VEGF Axis to Ameliorate Oxidative Damage‐Induced Inhibition of Bone Formation in MC3T3‐E1 Cells
Immunity, Inflammation and Disease · 2026-04 · 14 (4)
DOI: 10.1002/iid3.70412 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 06.04.2026. Verfasst von Shuo Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China. Hauptthemen laut MEDLINE: Oxidative Stress, Osteogenesis, Quercetin, Osteoblasts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Technology of Jilin Province, Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
This study aims to investigate how hyperoside (HYP) alleviates oxidative stress‐induced osteoporosis, its molecular mechanisms, and its impact on osteoblast differentiation, oxidative damage, and the estrogen‐PI3K/VEGF signaling pathway.
Methods
The osteoblast differentiation model was induced using dexamethasone, and osteoblast‐related markers like ALP, NO, GSH, MDA, and SOD were measured post‐HYP intervention. A zebrafish model was used to assess HYP's impact on ROS and bone formation. Network pharmacology identified key oxidative stress and osteoporosis targets, with HYP's binding affinity confirmed via molecular docking and simulation. RT‐qPCR verified the expression of key pathway targets.
Results
HYP can counteract dexamethasone‐induced inhibition of osteoblast differentiation, boost ALP, NO, GSH, and SOD levels, and lower MDA levels in osteoblasts. It also reduces ROS accumulation and enhances bone formation in zebrafish. Network pharmacology identified a common oxidative stress and osteoporosis target, with molecular docking confirming HYP's stable binding. RT‐qPCR showed HYP significantly upregulates SRC, PI3K, AKT1, and e‐NOS, activating the estrogen‐PI3K/VEGF pathway.
Conclusion
HYP plays an anti‐oxidative stress effect through targeted regulation of estrogen‐PI3K/VEGF signal axis, and then promotes osteoblast differentiation and bone formation, which provides a new potential candidate drug and experimental basis for the treatment of osteoporosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China.
- School of Pharmaceutical Sciences, Quality Evaluation & Standardization Hebei Province Engineering Research Center of Traditional Chinese Medicine, Hebei University of Chinese Medicine, Shijiazhuang, China.
ORCID-Profile: Jiaming Sun
Förderung
- Department of Science and Technology of Jilin Province
- Natural Science Foundation of China
- National Natural Science Foundation of China
- Hebei the Provincial Natural Science Foundation of China
Zitieren
APA
Wang, S., Feng, W., Feng, X., Wu, P., Zhang, N., Yang, X., Li, Y., Li, C., & Sun, J. (2026). Hyperoside Modulates the Estrogen‐PI3K/VEGF Axis to Ameliorate Oxidative Damage‐Induced Inhibition of Bone Formation in MC3T3‐E1 Cells. Immunity, Inflammation and Disease, 14(4). https://doi.org/10.1002/iid3.70412
Vancouver
Wang S, Feng W, Feng X, Wu P, Zhang N, Yang X, et al. Hyperoside Modulates the Estrogen‐PI3K/VEGF Axis to Ameliorate Oxidative Damage‐Induced Inhibition of Bone Formation in MC3T3‐E1 Cells. Immunity, Inflammation and Disease. 2026;14(4). doi:10.1002/iid3.70412
BibTeX
@article{Wang2026,
author = {Wang, Shuo and Feng, Wei and Feng, Xueqin and Wu, Peitong and Zhang, Nanxi and Yang, Xiaoqian and Li, Yawen and Li, Chunnan and Sun, Jiaming},
title = {Hyperoside Modulates the Estrogen‐PI3K/VEGF Axis to Ameliorate Oxidative Damage‐Induced Inhibition of Bone Formation in MC3T3‐E1 Cells},
journal = {Immunity, Inflammation and Disease},
year = {2026},
volume = {14},
number = {4},
doi = {10.1002/iid3.70412}
}
EUVIMED